Freenome, Inc. Common stock(FRNM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$10.41
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FRNM

11/13/2026: FRNM (1-star) is currently NOT-A-BUY. Pass it for now.

Freenome is a commercial-stage diagnostic company developing blood-based early cancer screening tests through an AI-powered multiomics platform. The company's primary strengths include its validated technology and an exclusive U.S. commercialization partnership with Abbott for its lead test, SimpleScreen CRC. Its core growth story centers on scaling non-invasive cancer screening adoption and expanding its portfolio into indications like lung cancer. Key risks include heavy reliance on commercial partners, intense competition in liquid biopsy, and ongoing net operating losses. The stock suits growth-oriented investors willing to accept volatility while monitoring commercial rollout milestones and reimbursement progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitFreenome offers high-growth potential driven by the commercial scaling of its innovative early cancer detection blood tests.
Momentum investorStrong fit while signal remains positiveMomentum appeal depends on positive market reactions to ongoing clinical data readouts and commercial rollout milestones.
Value investorWeak fitThe company is a development-stage diagnostics provider currently generating operating losses as it scales commercial operations.
Dividend investorWeak fitFreenome does not pay dividends, retaining all capital for clinical growth and product commercialization.
Low-risk investorWeak fitEarly-stage biotechnology and diagnostic stocks carry elevated clinical, regulatory, and market execution volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighPost-IPO stock prices can fluctuate significantly based on commercial adoption updates and market sentiment.
Valuation riskMedium / highValuations rely heavily on long-term adoption projections for early cancer screening products.
Competition risk (AI/multiomics and liquid biopsy competition)HighFreenome competes with well-funded diagnostics giants like Guardant Health and GRAIL.
Business qualityMediumProprietary multiomics technology is robust, but commercial infrastructure is still maturing.
Dividend incomeLow / noneNo dividend distributions are provided to investors.
Execution riskHighSuccess depends heavily on commercial execution partner Abbott and physician test adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.16B USD
Price to earnings Ratio -
1Y Target Price 18
Price to earnings Ratio -
1Y Target Price 18
Volume (30-day avg) 801.2K shares
Beta 0.6
52 Weeks Range 9.71 - 17.50
Updated Date 11/15/2026
52 Weeks Range 9.71 - 17.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.04

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Insufficient Data
PRICE PATH

Insufficient Data

The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
PRICE STABILITY

Insufficient Data

The stock price exhibits a Insufficient Data stability pattern.

Analysis of Past Performance

Type Stock
Historic Profit -6.02%
Avg. Invested days 39
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
FRNM receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
FRNM has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+20.1%) and strong revenue growth (+955.1%) are partially offset by weak cash generation (FCF margin -433.2%), weak profitability (net margin -721.3%).

Financial Health Rating

★★★★★
FRNM's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 36.7%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is FRNM's strongest growth driver at +955.1% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+20.1%, solid) and free-cash-flow growth (+48.7%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 51.1% and approximately 46.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 27.26% supports management-shareholder alignment.

Top 5 Institutional Investors

Sands Capital Ventures, LLC 0.00%
Aberdeen Group PLC 0.00%
Renaissance Technologies Corp 0.00%
Davy Asset Management Limited 0.00%
SVRN Asset Management, LLC 0.00%

Unit Economics (Per $1K Revenue)

★★★★★
FRNM generates approximately $-5,546 of gross profit, $-7,349 of operating income, and $-4,332 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
FRNM has a relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Personalized Cancer Detection (PCD) CommercializationRevenue generated from commercialized blood-based screening tests such as SimpleScreen CRC through distribution partners.The primary long-term engine driving product sales and market adoption.
Collaborations and License AgreementsMilestone payments and collaboration fees derived from partnerships with major healthcare companies like Abbott.Provides non-dilutive financial support and commercial validation during early market entry.

Earnings Date

Report Date 2026-11-10
When After Market
Estimate -
Actual 1.1

Profitability

Profit Margin -50.83%
Operating Margin (TTM) -43.81%

Management Effectiveness

Return on Assets (TTM) -10.36%
Return on Equity (TTM) -35.9%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 932.41M
Price to Sales(TTM) 5.33
Enterprise Value 932.41M
Price to Sales(TTM) 5.33
Enterprise Value to Revenue 30.66
Enterprise Value to EBITDA -
Shares Outstanding 111.50M
Shares Floating 51.37M
Shares Outstanding 111.50M
Shares Floating 51.37M
Percent Insiders 27.26
Percent Institutions 51.1

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.